Treating Rhabdomyosarcoma by Blocking KDM4B Enzyme - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Targeting the Accomplice: A Potential Treatment Approach for Rhabdomyosarcoma 08/03/2022 The fusion protein that drives the growth and survival of some rhabdomyosarcoma tumors relies on the KDM4B enzyme, researchers have found. Treating mice with a KDM4B-blocking drug and chemotherapy nearly eliminated rhabdomyosarcoma tumors with the fusion protein.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892